NCAN

What NCAN does

NCAN (National Center for Adaptive Neurotechnologies) is an NIBIB/NIH-funded research center operating as a federally designated Biomedical Technology Research Resource (BTRR). Founded in 1971 and headquartered in Albany, New York, with additional facilities at Washington University in St. Louis and the Shirley Ryan AbilityLab in Chicago, NCAN develops brain-computer interface (BCI) technologies and combined-therapy protocols aimed at restoring function in people with spinal cord injury, stroke, and other central nervous system disorders, including emerging work on PTSD and cognitive/behavioral conditions. At the center of its technology stack is BCI2000, a general-purpose software platform downloaded by research laboratories worldwide through bci2000.org, supplemented by research instruments such as SyncGenie (programmable event synchronization), EPOCS (Evoked Potential Operant Conditioning System), and a portable closed-loop cortical platform for evoked potential operant conditioning.

The center organizes its science around three Technology Research and Development projects (TRDs): TRD1 develops noninvasive BCI2000-based combined-therapy protocols for chronic spinal cord injury and stroke; TRD2 evaluates the same combined-therapy framework in animal models; and TRD3 develops ECoG/SEEG-based protocols for cognitive and behavioral disorders including PTSD. NCAN's intellectual framework rests on the proprietary Heksor model of skill acquisition in the changing nervous system and the Triple-Strategy combined-therapy framework, both used to design interventions that promote lasting functional recovery.

NCAN operates as an academic research consortium rather than a commercial enterprise. Its revenue is federal grant funding from NIBIB/NIH, not product sales; BCI2000 is distributed at no cost to academic users. The go-to-market model is community-led: dissemination occurs through peer-reviewed publication (796 papers in the research database), the annual Summer Course, recurring workshops, internships, and a BCI2000 user community, supported by core translational and clinical partnerships with Shirley Ryan AbilityLab, Washington University, and the Albany Stratton VA Medical Center. Patient-level outcomes, such as motor improvement across both proximal and distal upper extremities in 26 chronic hemiparetic stroke patients using IpsiHand BCI therapy, indicate clinical traction through partner-led translation rather than direct commercialization by NCAN itself.

Name

NCAN

Legal name

National Center for Adaptive Neurotechnologies

Website

https://neurotechcenter.org

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

11–50 employees

Short description

NCAN is an NIH/NIBIB-funded research center developing adaptive brain-computer interface technologies for neurological rehabilitation, anchored by its globally distributed BCI2000 software platform and serving neuroscience researchers and patients with stroke, spinal cord injury, and cognitive/behavioral disorders.

Ownership category

akta.pro rank

Product category

Neurotechnology Research Software

NAICS

Scientific Research and Development Services (5417), Other Computer Related Services (541519), Educational Support Services (61171)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

Keywords

• Brain-computer interface
• Neurotechnology research
• Neurorehabilitation software
• BCI software platform
• Adaptive neurotechnologies

Headquarters

HQ city

Albany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Government Research Funding: NCAN is funded as a Biomedical Technology Research Resource (BTRR) by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and the National Institutes of Health (NIH)

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NCAN develops and disseminates the BCI2000 general-purpose software platform for brain-computer interface research, alongside combined-therapy protocols targeting spinal cord injury, stroke, and cognitive/behavioral disorders. Its portfolio includes SyncGenie, EPOCS, and a portable closed-loop platform enabling cortical evoked potential operant conditioning for neurorehabilitation research worldwide.

Product overview

NCAN (National Center for Adaptive Neurotechnologies) is an NIBIB/NIH-funded research center that develops neurotechnologies for real-time adaptive interactions with the nervous system. At its core is BCI2000, a general-purpose software platform used worldwide by research laboratories. The center operates through three Technology Research and Development projects (TRDs): TRD1 focuses on noninvasive combined-therapy protocols for humans with spinal cord injury and stroke; TRD2 conducts animal studies for combined-therapy protocols; and TRD3 develops ECoG/SEEG-based protocols for cognitive/behavioral disorders including PTSD. Supporting products include SyncGenie (event synchronization device) and EPOCS (evoked potential operant conditioning system). NCAN also provides training programs, workshops, and summer courses to disseminate neurotechnology knowledge.

Differentiator

Problem solved

Functional benefit

Products and services

• BCI2000 BCI2000 is a general-purpose software platform for brain-computer interface research and applications, distributed to research laboratories worldwide via download registration at bci2000.org. It is the central software platform for all NCAN research and development activities and supports combined-therapy protocols, evoked potential operant conditioning, and related neuroscience experiments.
• SyncGenie SyncGenie is a programmable event synchronization device designed for neuroscience research, enabling precise timing synchronization across experimental setups. It was published in HardwareX (2025) by Alkhoury, Scanavini, Swissler, Shah, Gupta, and Hill.
• EPOCS (Evoked Potential Operant Conditioning System) EPOCS is a research tool and emerging therapy system for chronic neuromuscular disorders that enables operant conditioning of evoked potentials. It supports research applications and clinical translation toward treatment of neuromuscular conditions.
• Portable Closed-Loop Platform for Cortical Evoked Potential Operant Conditioning A portable closed-loop platform enabling cortical evoked potential operant conditioning, with validated target intensity estimation. Published in Biomedical Physics & Engineering Express (2026) by Gupta, Brangaccio, Mojtabavi, and Hill. It supports rehabilitation research in portable, non-laboratory settings.

Quantifiable outcome

• 26 prospectively enrolled chronic hemiparetic stroke patients achieved significant motor improvement in both proximal and distal upper extremity with IpsiHand BCI therapy
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• Shirley Ryan AbilitylabcoreStrategic or Co-development PartnerChicago-based rehabilitation research facility conducting spinal cord injury trials and hosting NCAN facilities for translational neurotechnology research
• Washington UniversitycoreStrategic or Co-development PartnerMajor research university with facilities hosting NCAN research activities, including brain tumor research, resting-state fMRI studies, andglioma patient studies
• Albany Stratton VA Medical CentercoreStrategic or Co-development PartnerVeterans Affairs medical center conducting sensory research on spinal cord injury in collaboration with NCAN

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Precision Neuroscience: Developer of high-resolution cortical interface technology for neurological applications. Comparable to NCAN's TRD3 ECoG-based work in intracortical recording and stimulation, though with a venture-backed commercial orientation.
• Paradromics: Clinical-stage BCI company developing high-data-rate neural interfaces for medical applications. Comparable to NCAN in BCI R&D focus targeting CNS disorders, but operating as a venture-backed commercial entity rather than NIH-funded consortium.
• Synchron: Clinical-stage BCI company developing the Stentrode endovascular interface for paralysis and communication. Comparable to NCAN in targeting motor rehabilitation through BCI, but with a commercial clinical-trial pathway rather than grant-funded research model.
• Neurolutions: Commercial developer of the IpsiHand BCI therapy — the same clinical BCI therapy referenced in NCAN's stroke outcomes research. Directly comparable as a translational BCI rehabilitation company operating in NCAN's primary therapeutic indication.

Direct peers

• Blackrock Neurotech: Pioneer in implantable BCI technology with decades of research-grade BCI platform development. Comparable to NCAN as a long-standing BCI research and platform organization, though more commercially oriented toward implantable hardware.
• BrainGate: Academic BCI research consortium developing intracortical BCI technology for restoring communication and mobility. Closely comparable to NCAN as a multi-institutional academic BCI research enterprise with overlapping investigator community.
• Wyss Center for Bio and Neuroengineering: Geneva-based neurotechnology research center developing BCI and neural engineering solutions for neurological and psychiatric conditions. Closely comparable to NCAN as a translational neurotechnology research center with a similar institute-style operating model.

Broad incumbents

• Neuralink: Well-capitalized commercial BCI developer building high-bandwidth implantable brain-computer interfaces. Comparable to NCAN in BCI domain focus, but with vastly greater capital, faster iteration cycles, and a commercial-first orientation.

Others

• Allen Institute for Brain Science: Large-scale nonprofit neuroscience research organization producing open neuroscience data, tools, and atlases. Comparable as a nonprofit, publicly-funded neuroscience research enterprise with complementary dissemination and tool-building missions.

Regional players

• Shirley Ryan AbilityLab: Chicago-based rehabilitation research hospital and NCAN's core partner, conducting spinal cord injury trials and translational neurotechnology research. Comparable in neurorehabilitation mission and serves as a clinical arm extending NCAN's research reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/neurotechcenter
• LinkedInlinkedin.com/company/national-center-for-adaptive-neurotechnologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NCAN